ANZMIG Publications

Here is a listing of some mycology related publications during the past 10 years involving at least 2 ANZMIG members.

Publications

2016

  • Morris AJ, et al. Mycological testing of clinical samples in Australasian pathology laboratories: wide diversity and room for improvement. Pathology. 2016 Aug 24. pii: S0031-3025(16)40227-8. doi: 10.1016/j.pathol.2016.07.004.

  • Halliday CL, et al.Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations. Int J Antimicrob Agents. 2016 Aug 12. pii: S0924-8579(16)30199-6. doi: 10.1016/j.ijantimicag.2016.07.005.

  • Kennedy KJ, et al. Mucormycosis in Australia: contemporary epidemiology and outcomes. Clin Microbiol Infect. 2016 Jan 20. pii: S1198-743X(16)00012-4. doi: 10.1016/j.cmi.2016.01.005.

2015

  • Halliday CL. et al., ​2015. Molecular diagnostic methods for invasive fungal disease: the horizon draws nearer? Pathology. 47(3):257-69. doi: 10.1097/PAT.0000000000000234. PubMed PMID: 25719852.

  • Kidd SE. et al.,​ 2015. Multi-triazole-resistant Aspergillus fumigatus infections in Australia. Mycoses. 58(6):350-5. doi: 10.1111/myc.12324. PubMed PMID: 25885568.

  • McMullan BJ. et al., 2015. Rapid microscopy and use of vital dyes: potential to determine viability of Cryptococcus neoformans in the clinical laboratory. PLoS One. 10(1):e0117186. doi: 10.1371/journal.pone.0117186.

  • Osowicki J. et al., 2015. Ahead of consensus: a paediatric antifungal prophylaxis census. Intern Med J. 45(3):364-5. doi: 10.1111/imj.12690.

  • Slavin M. et al., ​2015. Invasive infections due to filamentous fungi other than Aspergillus: epidemiology and determinants of mortality. Clin Microbiol Infect. 21(5):490.e1-490.e10.

  • Trubiano JA. et al., ​2015. Candida glabrata fungaemia at an Australian cancer centre: epidemiology, risk factors and therapy. Leuk Lymphoma. 24:1-9. PubMed PMID: 25907425.

  • Trubiano JA. et al., ​2015. Putting CYP2C19 genotyping to the test: utility of pharmacogenomic evaluation in a voriconazole-treated haematology cohort. J Antimicrob Chemother. 70(4):1161-5. doi: 10.1093/jac/dku529. PubMed PMID: 25558073.

2014

  • Blyth, C.C. et al., 2014. Consensus guidelines for the treatment of invasive mould infections in haematological malignancy and haemopoietic stem cell transplantation, 2014. Internal Medicine Journal, 44(12b), pp.1333–1349.

  • Chang, C.C. et al., 2014. Consensus guidelines for implementation of quality processes to prevent invasive fungal disease and enhanced surveillance measures during hospital building works, 2014. Internal Medicine Journal, 44(12b), pp.1389–1397.

  • Chau, M.M. et al., 2014. Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. Internal Medicine Journal, 44(12b), pp.1364–1388.

  • Chen, S.C. et al., 2014. Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014. Internal Medicine Journal, 44(12b), pp.1315–1332.

  • Coad, B.R. et al., 2014. Biomaterials surfaces capable of resisting fungal attachment and biofilm formation. Biotechnology advances, 32(2), pp.296–307.

  • Cooley, L. et al., 2014. Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. Internal Medicine Journal, 44(12b), pp.1350–1363.

  • Fleming, S. et al., 2014. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Internal Medicine Journal, 44(12b), pp.1283–1297.

  • Heng, S.-C. et al., 2014. Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies. Diagnostic Microbiology and Infectious Disease, 79(3), pp.322–327.

  • Macesic, N. et al., 2014. Protothecosis in hematopoietic stem cell transplantation: case report and review of previous cases. Transplant infectious disease : an official journal of the Transplantation Society, 16(3), pp.490–495.

  • Morrissey, C.O. et al., 2014. Consensus guidelines for the use of empiric and diagnostic-driven antifungal treatment strategies in haematological malignancy, 2014. Internal Medicine Journal, 44(12b), pp.1298–1314.

  • Slavin, M.A. et al., 2014. Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014. Internal Medicine Journal, 44(12b), pp.1267–1276.

  • van Hal, S.J., Chen, S.C.A., et al., 2014a. Support for the EUCAST and revised CLSI fluconazole clinical breakpoints by Sensititre® YeastOne® for Candida albicans: a prospective observational cohort study. Journal of Antimicrobial Chemotherapy, 69(8), pp.2210–2214.

  • van Hal, S.J., Gilroy, N.M., et al., 2014b. Survey of antifungal prophylaxis and fungal diagnostic tests employed in malignant haematology and haemopoietic stem cell transplantation (HSCT) in Australia and New Zealand. Internal Medicine Journal, 44(12b), pp.1277–1282.

2013

  • Chapman, J.R. et al., Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem? Kidney International, 84(2), pp. 240-3.

  • Chen S.C.A., Korman, T., Slavin, M. et al., 2013. Antifungal therapy and management of complications of cryptococcosis due to Cryptococcus gattii. Clinical Infectious Disease, 57: 543-551.

  • McMullan BJ, Sorrell TC, Chen SC. 2013. Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. Future Microbiol. 8, pp.1613-31.

  • Morrissey C.O., et al., 2013. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infectious Diseases, 13(6), pp.519-528.

  • Neoh, C.F. et al., 2013a. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC). Mycoses, 56(5), pp.532-42.

  • Neoh, C.F., et al., 2013b. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis. Internal Medicine Journal, 43(6), pp. 668-677.

2012

  • Ananda-Rajah, M.R., Grigg, A. et al., 2012a. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/ itraconazole in patients with acute myeloid leukemia/ myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica, 97(3), pp.459–463.

  • Ananda-Rajah, M.R., Slavin, M.A. & Thursky, K.T,. 2012b. The case for antifungal stewardship. Current Opinion in Infectious Diseases, 25(1), pp.107–115.

  • Boan, P. et al., 2012. Refractory Arthrographis kalrae native knee joint infection. Medical Mycology Case Reports. 1(1), pp. 112–114

  • Chen, S.C.-A. et al., 2012. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clinical Infectious Diseases, 55(6), pp.789–798.

  • Heng, S.-C. et al., 2012. Hospital costs, length of stay and mortality attributable to invasive scedosporiosis in haematology patients. Journal of Antimicrobial Chemotherapy, 67(9), pp.2274–2282.

  • McMullan, B.J. et al., 2012. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS ONE, 7(11), p.e49541.

  • Ananda-Rajah, M.R., Grigg, A., Slavin, M.A. 2012 Making sense of posaconazole therapeutic drug monitoring: a practical approach. Current Opinions in Infectious Diseases, 25(6), pp. 605-11.

2011

  • Ananda-Rajah, M.R. et al., 2011. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: an economic modeling approach. Antimicrobial Agents and Chemotherapy, 55(5), pp.1953–1960.

  • Blyth, C.C. et al., 2011. Skull-base osteomyelitis: fungal vs. bacterial infection. Clinical Microbiology and Infection, 17(2), pp.306–311.

  • Carriconde, F. et al., 2011. Clonality and α-a recombination in the Australian Cryptococcus gattii VGII population--an emerging outbreak in Australia. PLoS ONE, 6(2), p. e16936.

  • Chen, S.C.-A., Blyth, C.C., et al., 2011a. Pneumonia and lung infections due to emerging and unusual fungal pathogens. Seminars in Respiratory and Critical Care Medicine, 32(6), pp.703–716.

  • Chen, S.C.-A., Slavin, M.A. & Sorrell, T.C., 2011b. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs, 71(1), pp.11–41.

  • Harun, A. et al., 2011. Development and validation of a multiplex PCR for detection of Scedosporium spp. in respiratory tract specimens from patients with cystic fibrosis. Journal of Clinical Microbiology, 49(4), pp.1508–1512.

  • McCormack, J. and Pollard, J., 2011. Aspergillus endocarditis 2003-2009. Medical Mycology, 49 Suppl 1, pp. S30-4.

  • McMullan, B. et al., 2011. Prototheca wickerhamii mimicking yeast: a cautionary tale. Journal of Clinical Microbiology, 49(8), pp.3078-3081.

  • Morrissey, C.O. et al., 2011. Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leukemia & Lymphoma, 52(2), pp.179–193.

  • Neoh, C.F., Liew, D., et al., 2011a. Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis. Journal of Antimicrobial Chemotherapy, 66(8), pp.1906–1915.

  • Neoh, C.F., Snell, G.I., et al., 2011b. Antifungal prophylaxis in lung transplantation--a world-wide survey. American Journal of Transplantation, 11(2), pp.361–366.

  • Ong, A. et al., 2011. Fatal mycotic aneurysms due to Scedosporium and Pseudallescheria infection. Journal of Clinical Microbiology, 49(5), pp.2067–2071.

  • Trivedi, S.R. et al., 2011. Feline cryptococcosis: impact of current research on clinical management. Journal of Feline Medicine and Surgery, 13(3), pp.163–172.

2010

  • Blyth, C.C., Harun, A., et al., 2010a. Detection of occult Scedosporium species in respiratory tract specimens from patients with cystic fibrosis by use of selective media. Journal of Clinical Microbiology, 48(1), pp.314–316.

  • Blyth, C.C., Middleton, P.G., et al., 2010b. Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? Medical Mycology, 48 Suppl 1, pp.S37–44.

  • Chen, S.C.-A. et al., 2010. In vitro antifungal activities of bis(alkylpyridinium)alkane compounds against pathogenic yeasts and molds. Antimicrobial Agents and Chemotherapy, 54(8), pp.3233–3240.

  • Chong, H.S. et al., 2010. In vitro susceptibility of the yeast pathogen Cryptococcus to fluconazole and other azoles varies with molecular genotype. Journal of Clinical Microbiology, 48(11), pp.4115–4120.

  • Slavin, M.A. et al., 2010. Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. Journal of Antimicrobial Chemotherapy, 65(5), pp.1042–1051.

2009

  • Blyth, C.C. et al., 2009. Not Just Little Adults: Candidemia Epidemiology, Molecular Characterization, and Antifungal Susceptibility in Neonatal and Pediatric Patients. Pediatrics, 123(5), pp.1360–1368.

  • Chen, S.C.A. et al., 2009. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clinical Microbiology and Infection, 15(7), pp.662–669.

  • Heath, C.H. et al., 2009. Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. Clinical Microbiology and Infection, 15(7), pp.689–693.

  • Kidd, S.E., Ling, L.M., et al., 2009a. Molecular epidemiology of invasive aspergillosis: lessons learned from an outbreak investigation in an Australian hematology unit. Infection Control and Hospital Epidemiology, 30(12), pp.1223–1226.

  • Kidd, S.E., Nik Zulkepeli, N.A.A., et al., 2009b. Utility of a proposed CSP typing nomenclature for Australian Aspergillus fumigatus isolates: Identification of additional CSP types and suggested modifications. Journal of Microbiological Methods, 78(2), pp.223–226.

  • Hurst, S.F. et al., 2009. Interlaboratory reproducibility of a single-locus sequence-based method for strain typing of Aspergillus fumigatus. Journal of Clinical Microbiology, 47(5), pp.1562–1564.

  • Kesson, A.M. et al., 2009. Scedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case report. Clinical Infectious Diseases, 48(9), pp.1257–1261.

  • Marriott, D.J.E. et al., 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Critical care, 13(4), p.R115.

  • van Hal, S.J. et al., 2009. Candidemia following solid organ transplantation in the era of antifungal prophylaxis: the Australian experience. Transplant Infectious Disease, 11(2), pp.122–127.

2008

  • Ananda-Rajah, M.R., Grigg, A. & Slavin, M.A., 2008. Breakthrough disseminated Scedosporium prolificans infection in a patient with relapsed leukaemia on prolonged voriconazole followed by posaconazole prophylaxis. Mycopathologia, 166(2), pp.83–86.

  • Chang, C.C. et al., 2008. Preventing invasive fungal infection during hospital building works. Internal Medicine Journal, 38(6b), pp.538–541.

  • Kong, F. et al., 2008. Rapid identification and differentiation of Trichophyton species, based on sequence polymorphisms of the ribosomal internal transcribed spacer regions, by rolling-circle amplification. Journal of Clinical Microbiology, 46(4), pp.1192–1199.

  • Playford, E.G. et al., 2008. Candidemia in nonneutropenic critically ill patients: Risk factors for non-albicans Candida spp. Critical Care Medicine, 36(7), pp.2034–2039.

  • Slavin, M.A. et al., 2008. Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Internal Medicine Journal, 38(6b), pp.468–476.

  • Thursky, K.A. et al., 2008. Recommendations for the treatment of established fungal infections. Internal Medicine Journal, 38(6b), pp.496–520.

  • Troke, P. et al., 2008. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrobial Agents and Chemotherapy, 52(5), pp.1743–1750.

  • Worth, L.J. et al., 2008. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with haematological disorders. Internal Medicine Journal, 38(6b), pp.521–537.

2007

  • Morrissey, C.O. et al., 2007. Caspofungin as salvage monotherapy for invasive aspergillosis in patients with haematological malignancies or following allogeneic stem cell transplantation: efficacy and concomitant cyclosporin A. Mycoses, 50 Suppl 1, pp.24–37.

2005

  • Campbell, L.T. et al., 2005. Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryotic Cell, 4(8), pp.1403–1409.